<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102578">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995760</url>
  </required_header>
  <id_info>
    <org_study_id>201310037RINA</org_study_id>
    <nct_id>NCT01995760</nct_id>
  </id_info>
  <brief_title>The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?</brief_title>
  <official_title>The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate which is the most appropriate parameter correlates
      with clinical effectiveness of vancomycin: trough drug level or AUC/MIC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have shown AUC/MIC to be the better pharmacokinetic-pharmacodynamic
      parameter for clinical effectiveness of vancomycin. However, the 2009 consensus guideline
      for vancomycin therapeutic monitoring continued to recommend trough serum concentration
      monitoring in the clinical setting. In 2011, Patel et al showed that highly difference
      between AUC(72-96h) and Cmin(96h). Different dosing and creatinine clearance may reach the
      same trough drug level with different AUC. The investigators wonder whether trough drug
      level can serve as a substitute marker for AUC and as a parameter for vancomycin therapeutic
      monitoring.

      In this study, the investigators will calculate AUC/MIC of vancomycin with published
      formula, analyze its correlation with patient's clinical outcome and compare that with
      trough drug level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>Day 30 after index date (the date of positive methicillin-resistant Staphylococcus aureus blood culture)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Day 90 after index date (the date of positive methicillin-resistant Staphylococcus aureus blood culture)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Discharge day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Methicillin-resistant Staphylococcus Aureus Septicemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients of National Taiwan University Hospital. During the period of 2001/1/1 to
        2013/12/31, age above or equal to 20 year-old adult with positive methicillin-resistant
        Staphylococcus aureus blood culture who receiving vancomycin therapy with therapeutic
        monitoring.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatients of National Taiwan University Hospital

          -  Age above or equal to 20 years old

          -  Positive methicillin-resistant Staphylococcus aureus blood culture

          -  Receiving vancomycin therapy for definitive use

          -  Undergoing therapeutic drug monitoring (had serum vancomycin concentration level)

        Exclusion Criteria:

          -  Age below 20 years old

          -  Without details of vancomycin dose and frequency

          -  Vancomycin treatment shorter than 72 hours

          -  Without renal function data (serum creatinine level, creatinine clearance)

          -  Without infection-related clinical outcomes (lab data such as white blood cell count
             , seg, C reactive protein , body temperature records)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Jiuan Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-hua Wang</last_name>
    <phone>+886-2-33668785</phone>
    <email>momowang106@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsing-yu Lin</last_name>
    <phone>+886-2-33668793</phone>
    <email>r01451009@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Jiuan Shen</last_name>
      <phone>+886-2-33668792</phone>
      <email>ljshen@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vancomycin</keyword>
  <keyword>therapeutic response monitoring</keyword>
  <keyword>AUC/MIC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
